Supernus and Indivior complete merger

• Supernus completed its merger with Indivior on November 2, 2026, creating a combined CNS biopharmaceutical company operating as Supernus.
• The combined company begins trading on the Nasdaq Global Market under ticker SUPN on November 3, 2026.
• Former Supernus shareholders received 1.5401 common shares for each share held, giving them approximately 43.5% ownership; former Indivior shareholders own approximately 56.5%.
• Pre-closing Indivior shareholders will receive a one-time special cash dividend totaling $1 billion.
• The dividend is funded through a $650 million Citibank term loan facility, with the remainder covered by existing cash.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indivior Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-121013), on November 02, 2026, and is solely responsible for the information contained therein.